12Mar 2023
PD-L1 Expression in NSCLC: Comparison of Cytology Imprints, Circulating Tumor Cells, and Tumor Tissue

PD-L1 Expression in NSCLC: Comparison of Cytology Imprints, Circulating Tumor Cells, and Tumor Tissue

Alternative sources of tumour information need to be explored in patients with non‐small cell lung cancer (NSCLC). This study compared programmed cell death one ligand 1 (PD‐L1) expression on cytology imprints and circulating tumour cells (CTCs) with PD‐L1 tumour proportion score (TPS) from immunohistochemistry staining of tumour tissue from patients with NSCLC. The findings report that adding PD‐L1 expression in CTCs to cytology imprints markedly improved the prediction capacity for PD‐L1 positivity. The combined analysis of cytological imprints and CTCs provides information on the tumoral PD‐L1 status in NSCLC patients, which might be used when no tissue is available.

  • #oncology

Like

Save

Share